Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo

Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo

Abstract Modified Vaccinia virus Ankara (MVA) is a promising vaccine vector with an excellent safety profile. However, despite extensive pre-clinical and clinical testing, surprisingly little is known about the cellular tropism of MVA, especially in relevant animal species. Here, we performed in vit...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Arwen F. Altenburg, Carolien E. van de Sandt, Bobby W. S. Li, Ronan J. MacLoughlin, Ron A. M. Fouchier, Geert van Amerongen, Asisa Volz, Rudi W. Hendriks, Rik L. de Swart, Gerd Sutter, Guus F. Rimmelzwaan, Rory D. de Vries
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/ee315e57be3b4db7bdd91fe899f5fce5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares